Pharmaceutical

Growing Awareness to Boost Non-small Cell Lung Cancer (NSCLC) Therapeutics Market

Transparency Market Research has published a new market report titled, “Non Small Cell Lung Cancer Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.” According to the report, the global non small cell lung cancer market was valued at US$ 4.9 Bn in 2014 and is anticipated to expand at a CAGR of 12.1% from 2015 to 2023 to reach US$ 15.1 Bn in 2023.

Get Report Sample and Customize: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

The report provides detailed analysis of current and emerging drugs for non small cell lung cancer (NSCLC), segmenting them based on type of drug class. Drugs have been analyzed by segments such as angiogenesis inhibitor, EGFR inhibitor, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitor. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market in 2014. High demand for Avastin in major geographies such as Europe and the U.S. is likely to propel the segment during the forecast period. The angiogenesis inhibitor segment was valued at US$ 1,627.1 Mn in 2014 and is likely to account for US$ 2,020.4 Mn by 2023, expanding at a CAGR of 1.8% from 2015 to 2023.

NSCLC, often the most dreaded of all types of lung cancer, is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. Drugs used in the treatment of NSCLC range from regular regimens to targeted therapies. The drugs are based on simple chemistries to highly advanced complex protein. The market is witnessing strong growth due to high awareness among the population through government initiatives. Moreover, the drugs for NSCLC are given swift approvals by regulatory bodies and grants for research. This has led to new generation of drugs being introduced in the NSCLC market.

The folate antimetabolites segment is projected to be the second highest segment of the global NSCLC therapeutics market. The EGFR inhibitor and microtubule stabilizer segments held the third and fourth largest shares of the market in terms of revenue in 2014. However, entry of new targeted therapies with more surveillance rate could restrain market growth. PD-1/PD-L1 inhibitor is likely to the fastest growing segment during the forecast period, due to affectivity of the treatment as clinical data showed double survival rate. The non-small cell lung cancer therapeutics market is anticipated to be driven by increase in incidence and diagnosis rate, government initiatives leading to rapid approval of the treatment, and development of targeted therapies.

The major classes of drugs under NSCLC are angiogenesis inhibitor, EGFR blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitors. The angiogenesis inhibitor segment dominated the market in 2014. High efficacy, targeted therapies, and increasing demand in major geographies such as Europe, the U.S., and Japan are attributed to the dominance of the angiogenesis inhibitor segment in the NSCLC therapeutics market. Zykadia is expected to witness the highest growth rate during the forecast period, followed by Opdivo.

The report offers a detailed analysis of factors responsible for market growth and outlines a possible growth trajectory for other segments. The report is thus compiled with the primary objective of updating the stakeholders with the market dynamics, which are graphically illustrated.

AstraZeneca plc, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Novartis AG, Eli Lilly and Company, Pfizer, Inc., Genentech, Inc. (a Roche company), and Sun Pharmaceutical Industries Ltd. are the major companies operating in the global non small cell lung cancer therapeutics market. Genentech, a Roche company, was identified as the leading player in the global non-small cell lung cancer therapeutics market in 2014, accounting for a revenue share of more than 36%, followed by Eli Lilly and Company.

Full Research Report on Global Non Small Cell Lung Cancer Therapeutics Market with detailed figures and segmentation at: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Polymerase chain reaction (PCR) Technologies and Global Markets Report, 2013-2019

Polymerase chain reaction (PCR) is a simple and rapid method to amplify DNA, i.e. produce a large number of clones of DNA molecules from a sample. In the fields of molecular biology or molecular pathology, where the sample quality might be poor, PCR has become the most widely used technology. The market for PCR technology includes reagents and consumables, instruments, software and services. The reagents and consumables segment accounts for the largest share in this market, followed by the instruments segment. Growth of this market is fuelled by increased usage and wide applications in the fields of life sciences research, clinical diagnostics and drug discovery. Increasing number of patients suffering from cancer, AIDS and hepatitis and heavy investments in medical R&D are some other factors driving growth of this market.

Read More @ http://www.transparencymarketresearch.com/pcr-technologies.html

A paradigm shift in drug discovery technologies, from plant-derived chemicals to cellular and genetic components, has provided great impetus to the use of PCR technology. Pharmacogenomics processes are now increasingly utilizing genotyping and phenotyping methods for identification of clinical biomarkers. However, this market is characterized mainly by rapid technological advancements, indicating a highly competitive scenario for market players. Competitive pricing pressures have led to an intense struggle amongst key players, for retaining their market shares.

Various PCR techniques available in the market include Q-PCR, Reverse-Transcription PCR (RT-PCR), Inverse PCR and Assembly PCR, of which Q-PCR is the fastest growing technique in the market. Different application areas include research, DNA sequencing, tissue typing, infectious diseases, gene expression, diagnosis and others.

Some of the major players in this market are Abbott Laboratories, Affymetrix Inc., Agilent Technologies, Beckman Coulter Inc., Bio-Rad, Becton, Dickinson and Co., GE Healthcare, Sigma-Aldrich Corp. and Roche.

Download Full PDF: Global Polymerase Chain Reaction (PCR) Market Report, 2013-2019

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

  • North America

  • Asia Pacific

  • Europe

  • Rest of the World

This report provides comprehensive analysis of

  • Market growth drivers

  • Factors limiting market growth

  • Current market trends

  • Market structure

  • Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

More Reports on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

Contact:

Transparency Market Research

90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Injectable Targeted Therapy Market – Global Industry Research Report, 2014-2020

Targeted delivery is a clinical treatment used to deliver medication in patients to increase the concentration of medication in some parts of the body. Target specific drug delivery is localized, prolonged, targeted and have protected drug interaction with the diseased tissue. The advantage of injectable targeted therapy was the decrease in frequency of the dosages that are delivered to the patient, it more uniform effect of the drug, reduction of drug’s side-effects and reduced oscillation in circulating drug levels. The most important characteristics of targeted drug delivery system are non-toxic, non-immunogenic, both physically and chemically stable in-vivo and in-vitro and controllable and predictable rate of drug release.

Browse Full Report with TOC: http://www.transparencymarketresearch.com/injectable-targeted-therapy.html

The various types of delivery vehicles used in injectable targeted therapy are liposomes, micelles, dendrimers, biodegradable particles and artificial DNA nanostructures. The applications of injectable targeted therapy are widely classified such as cardiovascular diseases, respiratory diseases and diabetes, but the primary application of injectable targeted therapy is in oncology. The injectable drugs primary target range included oncology, hormonal imbalances, autoimmune diseases, orphan/rare diseases (Cystic Fibrosis, Ribose-5-phosphate isomerase deficiency or RPI deficiency, Hemophilia and Wilson’s disease) and others (allergies, aesthetic treatment hepatitis C and pain management).

The major drivers of injectable targeted therapy market are growing prevalence of senile disorders, sedentary lifestyle and increasing prevalence of cancer. According to World Health Organization (WHO), there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. While in same year 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions from African and Asian continent. The prevalence of cancer is expected to increase and predicted to reach 24 million by 2035.

North America was observed to be the largest market for injectable targeted therapy as it’s a technologically advanced and premium therapy; the highest clinical research studies on targeted therapy market are going in the U.S. and Canada. Followed by Europe, the novel injectable target therapy is applied in most of the oncology cases in United Kingdom, Germany, France, Italy and Spain. Asia-Pacific and Rest of the World (RoW) consists of most of the emerging markets in the world such as India, China, Brazil and Mexico. The injected targeted therapy market in these geographies is currently at initial stages while in Japan this dosage form was observed to be the therapy of choice in most of the oncology patient treatment. Overall demand for targeted drugs is expected to grow in these regions especially after expected breakthroughs in cardiovascular, respiratory and diabetes applications.

Download Full PDF: Injectable Targeted Therapy Market – Global Industry Analysis, Size, Share, Trends And Forecast 2014 – 2020

The global trend observed in injectable targeted therapy market was increased deals in targeted drug delivery companies and ventures are expected to drive the partnership research programs in this therapy market. Some of the major players in Injectable targeted therapy market are Becton Dickinson, SHL Group, Ypsomed Holding AG, Terumo Medical Corp. , Schott AG, Owen Mumford Ltd and Antares Pharma Inc. Some market players currently researching on this technology are Actavis plc, Astra Zeneca plc, GlaxoSmithKline, Merus Laboratories International Inc., National Cancer Institute, Novartis AG, Amgen, Bristol-Myers Squibb, Unilife Corporation, Ligand Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc. and others.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

  • North America

  • Asia Pacific

  • Europe

  • Rest of the World

This report provides comprehensive analysis of

  • Market growth drivers

  • Factors limiting market growth

  • Current market trends

  • Market structure

  • Market projections for upcoming years

More Reports on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

 

Hemorrhage Treatment Market – Global Analysis and Industry Forecast 2014 – 2020

Hemorrhage or bleeding is a medical condition in which a person experiences excessive bleeding due to various reasons such as underlying medical condition or traumatic injury or cancer. Hemorrhages usually occur internally or externally (through a natural opening such as nose, mouth, ear, vagina, urethra or anus). Generally, a healthy human being can endure blood loss of 10 – 15% of the total volume of blood without having any serious medical difficulties. However, various types of hemorrhagic diseases and conditions can be treated with the proper use effective drugs and treatment regimens. At present, hemorrhage treatments is a profitable market venture due to the large base of hypertensive patients and increasing research on potential drug molecules, which makes this industry a highly beneficial and attractive market.

Browse Full Report with TOC: http://www.transparencymarketresearch.com/hemorrhage-treatment-market.html

Some of the types of hemorrhages usually experienced by people are as follows:

  • Hematemesis

  • Hematochezia

  • Hematuria

  • Intracranial hemorrhage

  • Cerebral hemorrhage

  • Subarachnoid hemorrhage (SAH)

  • Postpartum hemorrhage

  • Pulmonary hemorrhage

  • Occult gastrointestinal bleed

  • Upper gastrointestinal bleed

  • Lower gastrointestinal bleed

  • Ovarian bleeding

In the geographical perspective, North America closely followed by Europe is the largest market for hemorrhage treatment market owing to the increasing incidence rate of postpartum and cerebral hemorrhages as well as traumatic injuries. According to the American College of Obstetricians and Gynecologists (ACOG), in the U.S., approximately 7-10 women per 100,000 live births witness direct pregnancy-related maternal mortality. Moreover, according to the British Medical Journal, one woman in every 100,000 women witnesses postpartum hemorrhages during delivery. Furthermore, according to the WHO high blood pressure is estimated to cause 7.5 million deaths worldwide, which is alternatively driving the growth of the overall hemorrhage treatment market. However, other regions such as South East Asia, Latin America and Middle East are expected to be the potential markets in the near future. Owing to the increasing base of cerebral hemorrhage patients and high adoption rate for novel therapies, these regions are expected to be the potential market in the near future.

Some of the major factors driving the growth of the hemorrhage treatment market are increasing incidence rate of various types of hemorrhages and introduction of novel drugs with high effectiveness and less side effects. Moreover, other factors such as escalating number of patients suffering from high blood pressure and increasing number of traumatic injury cases are expected to propel the growth of the overall hemorrhage treatment market. Furthermore, high demand for safe and effective pharmacological therapies along with increased life expectancy among population is also expected to fuel the growth of this market. In addition, technological breakthrough such as point-of-care drug delivery systems and increased focus on retaining superior quality of life are some of the factors contributing in the growth of this market. However, rise in overall healthcare expenditure, stringent regulatory approvals and high product development costs are some of the market-restraining factors that might hamper the growth of the hemorrhage treatment market in the future.

Currently, the hemorrhage treatment market is a highly fragmented and mature market due to the participation of many established as well as emerging players in this industry. Some of the major players in Hemorrhage Treatment market are AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited and The Medicines Company, amongst others.

Download Full PDF: Hemorrhage Treatment Market – Global Industry Analysis, Size, Share, Trends And Forecast 2014 – 2020

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

  • North America

  • Asia Pacific

  • Europe

  • Rest of the World

This report provides comprehensive analysis of

  • Market growth drivers

  • Factors limiting market growth

  • Current market trends

  • Market structure

  • Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players.

More Reports on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

 

Critical Limb Ischemia Treatment Market – Global Industry Analysis, Trends And Forecast 2014 – 2020

Critical limb ischemia (CLI) is a kind of peripheral arterial disease (PAD) in which chronic inflammation associated with atherosclerosis (progressive thickening of arteries lining) causes reduced blood flow to the extremities (legs, feet and hands), leading to severe pain and ulcers or sore. Some major risk factors for critical limb ischemia comprise aging (people aged 60 or over are at high risk of developing this diseased condition), diabetes, obesity, high cholesterol level, sedentary lifestyle, smoking and high blood pressure. Critical limb ischemia is associated with most common symptoms such as severe pain and numbness in the legs and feet when a person is in sedentary stage (rest pain), ulcers or skin sores and tissue necrosis (gangrene).

Browse Full Report with TOC: http://www.transparencymarketresearch.com/critical-limb-ischemia-treatment.html

Critical limb ischemia being severe condition of PAD does not improve on its own and requires comprehensive treatment by a vascular surgeon. Treatment focuses on reducing the number of risk factors, relieving pain, reduction of blood pressure and cholesterol level, and to preserve the limb. However, there is no specific drug approved by the United States Food and Drug Administration (FDA) for treating CLI. There are many companies including Aastrom Biosciences, Biotronik AG, United Therapeutics and Sanofi that are striving to develop drug meant to cure CLI and PAD. Endovascular therapy is one of the common options in the care of CLI. Angioplasty, stents, laser atherectomy and directional atherectomy are some major endovascular procedures that are used to treat critical limb ischemia. Treatment may also involve surgical procedure for removing arterial blockage.

Worldwide increasing geriatric population, rising incidence of CLI and participation of a large number of companies to develop drugs supposed to treat CLI are among the major factors driving the market growth across the globe. Statistics released by the United Nations (UN) suggest that the global share of elderly population (aged 60 years and over) as a proportion of the global population has been increased from 9.2% in 1990 to 11.7% in 2013, and is expected to reach 21.1% by the end of 2050. In 2013, nearly 841 million people were aged 60 years and over which is likely to reach more than 2 billion by 2050.

As people age they are at high risk of developing CLI, therefore, increasing elderly population is expected to drive the market growth during the forecast period. According to Vascular Disease Management, the prevalence of CLI has been estimated to be 300 per million inhabitants. In the United States, approximately 1 million people are affected with CLI. However, an analysis suggested by the Sage Group indicates that nearly 2 million people in the U.S. are living with CLI and owing to continuous rise in geriatric population the prevalence is expected to reach 3.5 million by 2020. Such high prevalence of people with CLI represents a favorable market for critical limb ischemia treatment market. In terms of geography, North America, Europe, Asia-Pacific and Rest of the World (RoW) are the four major markets for critical limb ischemia. Of these North America represents the largest market, followed by Europe, Asia-Pacific and Rest of the World (RoW).

Some of the major companies and research institution that are actively participating to develop medicines for treating critical limb ischemia include Aastrom Biosciences, Mahidol University, University Hospital Ostrava, MultiGene Vascular Systems Ltd. University of Southern California, Harvest Technologies, Seoul Veterans Hospital, GWT-TUD GmbH, Biotronik AG, United Therapeutics, Sanofi, Asklepios Kliniken Hamburg GmbH, Anesiva, Inc. and medac GmbH.

Download Full PDF: Critical Limb Ischemia Treatment Market – Global Industry Analysis, Size, Share, Trends And Forecast 2014 – 2020

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of

  • Market growth drivers

  • Factors limiting market growth

  • Current market trends

  • Market structure

  • Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

More Reports on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

Contact:

Transparency Market Research

90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Global DNA Vaccines Market – Trends and Industry Segment Forecast, 2012-2018

Vaccines have been in use since decades to provide immunological responses against diseases. A conventional vaccine is a biological preparation of weakened or attenuated, killed forms of a microbe or one of its cellular components, while a DNA vaccine is composed of genetically engineered DNA. When a DNA vaccine is injected into the cells of an organism, it stimulates organism’s immune system to produce immunity against the encoded antigens. DNA vaccines have a number of advantages over conventional vaccines such as when a conventional vaccine is administered, it activates only antibody reaction while a DNA vaccine activates antibody as well as cell mediated reaction. This new generation vaccine also offers fewer side effects compared to conventional vaccines.

Browse Full Report with TOC: http://www.transparencymarketresearch.com/dna-vaccines-market.html

The market for DNA vaccines is segmented into human DNA vaccines and animals DNA vaccines market. Currently there are no approved DNA vaccines for human but more than 100 products are under clinical trial for a variety of diseases including HIV infection, cancer and infectious diseases. Pennsylvania based Inovio Pharmaceuticals has it’s Syncon brand of vaccines in clinical trial for a variety of cancers and infectious diseases. On the other hand there are three DNA vaccines approved for animal health. The first vaccine was approved in the year 2005 for use in horses against West Nile Virus. Some of the pipeline DNA vaccines developed by Vical are Apex IHN for infectious hematopoietic necrosis virus and ONCEPT for melanoma in dogs.

The global market for DNA vaccines is growing impressively under the influence of advantages associated with this new generation of vaccines such as fewer side effects, ease of development and lower cost and continued development in biotechnology arena. The human health segment is expected to grow at relatively higher CAGR compared to animal health segment. Some of the notable companies operating in this market are Novartis Animal Health, Inovio Biomedical Corp, Merck & Co., Dendreon Corporation, Astellas Pharma, Vical, Sanofi and Tekmira Pharmaceuticals.

Download Full PDF: Industrial Report Global DNA Vaccines Market Analysis and Forecast 2013 – 2019

This research report analyzes this market depending on its market segments, major geographies, and current market trends.

Geographies analyzed under this research report include

  • North America

  • Asia Pacific

  • Europe

  • Rest of the World

This report provides comprehensive analysis of

  • Market growth drivers

  • Factors limiting market growth

  • Current market trends

  • Market structure

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

More Reports on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

 About Us

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

Contact:

Transparency Market Research

90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

 

Global Hepatitis C Therapeutics Market – Industry Analysis and Forecast, 2014-2020

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on “Hepatitis C Therapeutics Market“. This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Hepatitis is defined as the inflammation of the liver due to an infection by a virus or other causative organism or toxin. Hepatitis C on the other hand, is primarily as a result of the infection by hepatitis C virus (HCV). With a cure rate between 50%-80%, and no commercially available vaccine as of yet, hepatitis C is considered a deadly disease with a moderate to high infection rate. It is the leading cause for liver transplantation in the U.K and North America.

Read More @http://www.transparencymarketresearch.com/hepatitis-c-therapeutics-market.html

The transmission of this virus in a majority occurs from injectables drug abuse, as the virus can only be transmitted via blood-to-blood contact. The secondary transmission factors include tattooing, sexual contact, healthcare (blood transfusion, organ transplant) mishaps, and other rare unknown cases. HIV infected individuals and AIDS patients too are at a higher risk of infection. The diagnosis of Hepatitis C is also very tricky as there lays a risk of misdiagnosis as the virus can go undetected in a liver biopsy sample. Liver enzyme levels may remain normal for an infected person for years, in some cases an infected person may go as long as 30 years without showing any symptoms of infection.

PCR amplification of purified and centrifuged biopsy samples done at specified time intervals are the best proven method for near accurate diagnosis.

This process is done so as to remove any errors caused as a result of false negatives by antibody immunoassay testing. However since PCR testing is quite expensive, initial screening is usually done via immunoassay method, in addition, immunoassay also determines the viral load and thereby help identify the stage of infection between acute and chronic. The acute stage of disease can generally be cured in majority of the cases, in some cases spontaneous curing has also been observed. Complete cure rate cannot be a possibility as Hepatitis C virus has various strains and is found to be mutative in nature. Chronic cases are seen in a majority of infected individuals and are also curable in some cases, but again among the majority, liver cirrhosis is observed, which may then require liver transplantation. Transplantation requires to be done with continuous medication, as chances of reinfection are very high. Therapy for Hepatitis C is not definitive but is generally done with a combination of medicines, namely pegylated-interferon-alpha and ribavirin, which is an antiviral. Other medications include boceprevir, ledipasvir, telaprevir, sofosbuvir and the novel simeprevir and sovaldi. These are either given as an addition to ribavirin or as a replacement, depending upon the condition, contraindication, genotype of virus and patient history.

At present the cost of the antiviral and interferon market remains the biggest hurdle for the proliferation of Hepatitis C therapeutics market. The prices vary from few hundred dollars to hundreds of thousands of dollars for a single dose. Insurances companies generally do not cover the complete cost of drugs in standard covers, often individuals who have very high premium are the only ones able to afford the treatment. The ongoing research into vaccination may also provide as a restraint in the future, as preventive vaccination has always shown greater success versus therapeutics.

The market for Hepatitis C therapeutics remains in billions, with new combinations being patented every year, and each having their own market segment. They are at present one of the most sought after investment segment in the healthcare drugs industry. With entry of Asian players the prices too are bound to decrease, thereby potentially increasing therapeutics market. The North American market is the highest market by volume, followed by Europe, as in these regions reported cases are high in number, and so is the affordability of drugs.

The major cause for Hepatitis C transmission in developed nations is intravenous narcotic/psychedelic drug abuse, which is common in these regions. In developing markets of Asia and South America, the leading cause for transmission is healthcare exposure and their poor standards. This along with their population size make for a large market, however unavailability of affordable drugs is often the reason why markets haven’t been proliferated as of yet. However the recent growth of market in Asia Pacific is a positive sign for potential manufacturers. The rest of the world also follows a similar pattern.

Download Full PDF: Hepatitis C Therapeutics Market – Global Industry Analysis, Size, Share, Trends And Forecast 2014 – 2020

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

  • North America

  • Asia Pacific

  • Europe

  • Rest of the World

This report provides comprehensive analysis of

  • Market growth drivers

  • Factors limiting market growth

  • Current market trends

  • Market structure

  • Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

More Reports on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html